Related Experiment Video

Updated: Nov 8, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

643

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Jing-Zhou Hou1,2, Jing Christine Ye3,4, Jeffrey J Pu5,4

  • 1Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC), 5115 Centre Ave., Fl 4, Pittsburgh, PA, 15232, USA. houj@upmc.edu.

Journal of Hematology & Oncology
|April 21, 2021
PubMed

Insights

Novel immunotherapies like CAR-T cells and targeted small molecule inhibitors are advancing cancer treatment. This summary highlights key updates on these agents for hematological malignancies from the 2020 ASH meeting.

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Chimeric antigen receptor-engineered T cells (CAR-T) and antibody therapies are vital in cancer immunotherapy.
  • Biomarker-driven, chemotherapy-free small molecule inhibitors target key enzymes and oncoproteins in hematological malignancies.

Observation:

  • The 2020 American Society of Hematology (ASH) Annual Meeting presented significant updates on novel agents and regimens.
  • Key developments included LOXO-305, asciminib, universal CAR-T cells, and BCMA-directed immunotherapeutics.
  • Discussions also covered clinical trial data for numerous new treatments.

Findings:

  • The study synthesizes the latest advancements in novel agents and treatment regimens for hematological malignancies presented at the 2020 ASH meeting.
  • Updates reflect progress in targeted therapies and cellular immunotherapies.

Implications:

  • These advancements offer new therapeutic strategies for patients with hematological malignancies.
  • The findings underscore the rapid evolution of personalized and targeted cancer treatments.
Keywords:
Antibody–drug conjugateAsciminibBCMABiTECAR-TLOXO-305

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
621
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
2.3K